NCT05127057 (PRIME-RCT) is a NA clinical trial of PRIME Parkinson Care in Parkinsonism, sponsored by University of Bristol.

Who is sponsoring NCT05127057?

NCT05127057 is sponsored by University of Bristol.

What drugs are being tested in NCT05127057?

Interventions in NCT05127057: PRIME Parkinson Care, Usual Care.

What condition does NCT05127057 study?

NCT05127057 studies Parkinsonism.

Is NCT05127057 still recruiting?

NCT05127057 is currently completed. Last updated 29 September 2025.

Last reviewed 2025-09-29 · How we verify

NCT05127057: PRIME-RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)

Completed NA Last updated 29 September 2025

What this trial tests

NA trial testing PRIME Parkinson Care in Parkinsonism in 214 participants. Completed in 12 June 2025.

Timeline

28 October 2022

Primary endpoint
3 June 2025

12 June 2025

Quick facts

Lead sponsor	University of Bristol
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	214
Start date	28 October 2022
Primary completion	3 June 2025
Estimated completion	12 June 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

PRIME Parkinson Care
Usual Care

Conditions studied

Parkinsonism — all drugs for Parkinsonism →

Sponsor

University of Bristol

Who can join

18 and older, any sex, with Parkinsonism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life. Symptoms emerge and evolve as the disease progresses. Current care models are often inadequate to meet their needs. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Interventions for preventing falls in Parkinson's disease.
Allen NE, Canning CG, Almeida LRS, Bloem BR, et al · · 2022 · cited 50× · PMID 35665915 · DOI 10.1002/14651858.cd011574.pub2
Exploring how PRIME-Parkinson care is implemented and whether, how and why it produces change, for who and under what conditions: a protocol for an embedded process evaluation within the PRIME-UK randomised controlled trial.
Lloyd K, Tenison E, Smith S, Lithander F, et al · · 2025 · PMID 39894518 · DOI 10.1136/bmjopen-2024-086353
Operationalizing goal setting as an outcome measure in trials involving patients with frailty, multimorbidity or complexity.
Tenison E, Lloyd K, Ben-Shlomo Y, Henderson EJ. · · 2025 · PMID 39759567 · DOI 10.1016/j.conctc.2024.101411
Exploring how PRIME-Parkinson care is implemented and whether, how and why it produces change, for who and under what conditions: a protocol for an embedded process evaluation within the PRIME-UK randomised controlled trial
Lloyd K, Tenison E, Smith S, Lithander F, et al · · 2024 · DOI 10.1101/2024.12.23.24319541

Verify or expand the search:

Other recruiting trials for Parkinsonism

Currently open trials in the same condition.

NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT07386015 — Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG) · recruiting
NCT07207096 — Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerativ · recruiting
NCT06501469 — Biomarkers in Parkinsonian Syndromes · recruiting
NCT05171205 — Spinal Cord Stimulation for Parkinsonism · NA · recruiting

Other University of Bristol trials

Trials by the same sponsor.

NCT04226248 — CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) · Phase 3 · completed
NCT02841527 — Gastric Bypass, Gastric Band or Sleeve Gastrectomy to Treat Obesity · NA · completed
NCT02681848 — What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinic · unknown
NCT03408275 — Dietry Pattern and Lead Levels in Pregnancy · completed
NCT03407391 — Antecedent Picky Eating Behaviour in Young Children · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05127057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bristol
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05127057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing